| Original language | English (US) |
|---|---|
| Pages (from-to) | 533-535 |
| Number of pages | 3 |
| Journal | British Journal of Haematology |
| Volume | 154 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2011 |
Fingerprint
Keywords
- Angiogenesis
- Bevacizumab
- Multiple myeloma
- Thalidomide
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Hematology
Cite this
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma : A California Cancer Consortium trial. / Somlo, George; Lashkari, Ashkan; Bellamy, William; Zimmerman, Todd M.; Tuscano, Joseph; O'Donnell, Margaret R.; Mohrbacher, Ann F.; Forman, Stephen J.; Frankel, Paul; Chen, Helen X.; Doroshow, James H.; Gandara, David R.
In: British Journal of Haematology, Vol. 154, No. 4, 08.2011, p. 533-535.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma
T2 - A California Cancer Consortium trial
AU - Somlo, George
AU - Lashkari, Ashkan
AU - Bellamy, William
AU - Zimmerman, Todd M.
AU - Tuscano, Joseph
AU - O'Donnell, Margaret R.
AU - Mohrbacher, Ann F.
AU - Forman, Stephen J.
AU - Frankel, Paul
AU - Chen, Helen X.
AU - Doroshow, James H.
AU - Gandara, David R
PY - 2011/8
Y1 - 2011/8
KW - Angiogenesis
KW - Bevacizumab
KW - Multiple myeloma
KW - Thalidomide
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=79960846565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960846565&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08623.x
DO - 10.1111/j.1365-2141.2011.08623.x
M3 - Article
VL - 154
SP - 533
EP - 535
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 4
ER -